Intracranial germ cell tumors: an underrecognized diagnostic consideration in adults with sellar/suprasellar lesions.

IF 3.4 2区 医学 Q2 CLINICAL NEUROLOGY
Shirui Wang, Yining Zhen, Yong Yao, Lian Duan, Xin Lian, Linjie Wang, Shi Chen, Hui Pan, Lin Lu, Fengying Gong, Kan Deng, Yi Zhang, Bing Xing, Hui You, Feng Feng, Xinxin Mao, Xiaoyuan Li, Huijuan Zhu
{"title":"Intracranial germ cell tumors: an underrecognized diagnostic consideration in adults with sellar/suprasellar lesions.","authors":"Shirui Wang, Yining Zhen, Yong Yao, Lian Duan, Xin Lian, Linjie Wang, Shi Chen, Hui Pan, Lin Lu, Fengying Gong, Kan Deng, Yi Zhang, Bing Xing, Hui You, Feng Feng, Xinxin Mao, Xiaoyuan Li, Huijuan Zhu","doi":"10.1007/s11060-026-05737-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Sellar/suprasellar intracranial germ cell tumors (iGCTs) predominantly occur in children and adolescents, while adult-onset cases are rare and poorly characterized. We aimed to characterize adult-onset iGCTs and improve their differential diagnosis.</p><p><strong>Methods: </strong>Patients with iGCTs and onset age ≥ 18 years were enrolled in a single center. Adult-onset LYH patients served as comparison. iGCT and LYH were diagnosed using predefined pathological or clinical criteria incorporating characteristic clinical presentations, laboratory findings, MRI features, and treatment response. A nomogram was developed to distinguish iGCTs from LYH and was internally validated using 1,000 bootstrap resamples.</p><p><strong>Results: </strong>Forty-eight adult patients with iGCTs were enrolled, including 36 with germinoma and 12 with nongerminomatous germ cell tumors. The median age at onset was 23.4 years (range 18.1-53.5), and 87.5% were male. Forty-six patients with LYH were included for comparison. CSF β-hCG accurately diagnosed iGCTs from LYH (AUC 0.897, 95% CI 0.821-0.973). The optimal cutoff was 2.52 U/L, yielding a sensitivity of 78.6% and a specificity of 95.5%. The nomogram incorporating sex, log-transformed serum β-hCG, hyperprolactinemia, and pituitary stalk thickening differentiated iGCTs from LYH with an AUC of 0.939 (95% CI 0.875-1.000). Among patients with documented treatment regimens, 17 (53.1%) underwent radiotherapy, and 15 (46.9%) received chemoradiotherapy. During a median follow-up of 1.7 years (range 0.2-13.5), four patients developed progression or recurrence.</p><p><strong>Conclusions: </strong>iGCT represents a rare yet possible etiology of suprasellar/sellar lesions in adults. CSF β-hCG and the proposed nomogram may aid differential diagnosis, although external validation in independent cohorts is still required.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"179 3","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuro-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11060-026-05737-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Sellar/suprasellar intracranial germ cell tumors (iGCTs) predominantly occur in children and adolescents, while adult-onset cases are rare and poorly characterized. We aimed to characterize adult-onset iGCTs and improve their differential diagnosis.

Methods: Patients with iGCTs and onset age ≥ 18 years were enrolled in a single center. Adult-onset LYH patients served as comparison. iGCT and LYH were diagnosed using predefined pathological or clinical criteria incorporating characteristic clinical presentations, laboratory findings, MRI features, and treatment response. A nomogram was developed to distinguish iGCTs from LYH and was internally validated using 1,000 bootstrap resamples.

Results: Forty-eight adult patients with iGCTs were enrolled, including 36 with germinoma and 12 with nongerminomatous germ cell tumors. The median age at onset was 23.4 years (range 18.1-53.5), and 87.5% were male. Forty-six patients with LYH were included for comparison. CSF β-hCG accurately diagnosed iGCTs from LYH (AUC 0.897, 95% CI 0.821-0.973). The optimal cutoff was 2.52 U/L, yielding a sensitivity of 78.6% and a specificity of 95.5%. The nomogram incorporating sex, log-transformed serum β-hCG, hyperprolactinemia, and pituitary stalk thickening differentiated iGCTs from LYH with an AUC of 0.939 (95% CI 0.875-1.000). Among patients with documented treatment regimens, 17 (53.1%) underwent radiotherapy, and 15 (46.9%) received chemoradiotherapy. During a median follow-up of 1.7 years (range 0.2-13.5), four patients developed progression or recurrence.

Conclusions: iGCT represents a rare yet possible etiology of suprasellar/sellar lesions in adults. CSF β-hCG and the proposed nomogram may aid differential diagnosis, although external validation in independent cohorts is still required.

颅内生殖细胞肿瘤:一个未被充分认识的诊断考虑成人鞍/鞍上病变。
目的:鞍/鞍上颅内生殖细胞瘤(igct)主要发生于儿童和青少年,而成人发病病例罕见且特征不明确。我们的目的是表征成人发病的igct,并提高其鉴别诊断。方法:igct患者,发病年龄≥18岁,入组单一中心。以成人发病的LYH患者为对照。iGCT和LYH的诊断使用预先定义的病理或临床标准,包括特征性临床表现、实验室发现、MRI特征和治疗反应。开发了一种nomogram来区分igct和LYH,并使用1000个bootstrap样本进行内部验证。结果:纳入48例igct成年患者,其中36例为生殖细胞瘤,12例为非生殖细胞瘤性生殖细胞瘤。中位发病年龄为23.4岁(18.1-53.5岁),87.5%为男性。纳入46例LYH患者进行比较。CSF β-hCG能准确诊断LYH的igct (AUC 0.897, 95% CI 0.821-0.973)。最佳临界值为2.52 U/L,灵敏度为78.6%,特异性为95.5%。结合性别、对数转化血清β-hCG、高泌乳素血症和垂体柄增厚的nomogram将igct与LYH区分开来,AUC为0.939 (95% CI 0.875-1.000)。在有记录的治疗方案中,17例(53.1%)接受了放疗,15例(46.9%)接受了放化疗。在中位随访1.7年(0.2-13.5年)期间,4例患者出现进展或复发。结论:iGCT显示成人鞍上/鞍上病变罕见但可能的病因。脑脊液β-hCG和建议的nomogram可能有助于鉴别诊断,尽管仍需要独立队列的外部验证。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Neuro-Oncology
Journal of Neuro-Oncology 医学-临床神经学
CiteScore
6.60
自引率
7.70%
发文量
277
审稿时长
3.3 months
期刊介绍: The Journal of Neuro-Oncology is a multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research. The Journal of Neuro-Oncology does not seek to isolate the field, but rather to focus the efforts of many disciplines in one publication through a format which pulls together these diverse interests. More than any other field of oncology, cancer of the central nervous system requires multi-disciplinary approaches. To alleviate having to scan dozens of journals of cell biology, pathology, laboratory and clinical endeavours, JNO is a periodical in which current, high-quality, relevant research in all aspects of neuro-oncology may be found.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书